Sign In
Buy EVR
$340.09
-6.97 (-2.01%)
At Close: Jun 03, 2026
TG Therapeutics to Participate in the Evercore HealthCONx Conference
08:00am, Friday, 29'th Nov 2024
Fireside chat scheduled for Tuesday, December 3, 2024, at 10:00 AM ET Fireside chat scheduled for Tuesday, December 3, 2024, at 10:00 AM ET
Atara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx Conference
04:01pm, Wednesday, 27'th Nov 2024
THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell pl
Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference
09:00am, Wednesday, 27'th Nov 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference.
Evercore ISI's Mark Mahaney on why Amazon and Uber are his top two stock picks
08:41am, Wednesday, 27'th Nov 2024
Mark Mahaney, Evercore ISI head of internet research, joins 'Squawk Box' to discuss the latest market trends, state of internet and tech stocks, his top stock picks, and more.
Carisma Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
07:30am, Wednesday, 27'th Nov 2024
PHILADELPHIA , Nov. 27, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing in
Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference
04:01pm, Tuesday, 26'th Nov 2024
LONDON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the 7th Annual Evercore ISI
Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference
04:00pm, Tuesday, 26'th Nov 2024
NEWTON, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amylo
Nuvation Bio to Present at the 7th Annual Evercore ISI HealthCONx Conference
08:00am, Tuesday, 26'th Nov 2024
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hun
Rocket Pharmaceuticals to Participate in the 7th Annual Evercore HealthCONx Conference
07:00am, Tuesday, 26'th Nov 2024
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord
SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
07:00am, Tuesday, 26'th Nov 2024
STAMFORD, Conn., Nov. 26, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announc
Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference
07:00am, Tuesday, 26'th Nov 2024
BOSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral
Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference
06:00pm, Monday, 25'th Nov 2024
TEL AVIV, Israel, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, and Eric Hughes, Teva's Ex
Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
05:11pm, Monday, 25'th Nov 2024
WALTHAM, Mass. , Nov. 25, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combin
Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference
09:30am, Monday, 25'th Nov 2024
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to participate in a fireside chat
Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference
08:15am, Monday, 25'th Nov 2024
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (T
